Methylation status of insulin-like growth factor-binding protein-3 promoter in prostate cancer tissues

Asia-Pacific Journal of Clinical Oncology

Volumn 2, Issue 3, 2006, Pages 144-149

  Okugi, Hironobu ^a   Koike, Hidekazu ^a   Sekine, Yoshitaka ^a   Matsui, Hiroshi ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

IGFBP 3; Methylation; Prostate cancer

Indexed keywords

BISULFITE; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA EXTRACTION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN METHYLATION; RESTRICTION MAPPING;

EID: 33747374110     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2006.00055.x     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Nakata S, Sato J, Ohtake N, Yamanaka H. Regional and chronological differences of urogenital cancer death in Japan. Int J Urol 1996; 87: 1313-20.
3. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991; 73: 401-7.
4. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
5. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 1994; 26: 81-4.
6. Stewart CE, Rotwein P. Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005-26.
7. Chan JM, Stampfer MJ. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-106.
8. Deal C, Ma J, Wilkin F et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001; 86: 1274-80.
9. Wang L, Habuchi T, Tsuchiya N et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003; 63: 4407-11.
10. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993; 3: 226-31.
11. Yamanaka M, Watanabe M, Yamada Y et al. Altered methyation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106: 382-7.
12. Woodson K, Gillespie J. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate 2004; 60: 25-31.
13. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514-19.
14. Jeronimo C, Henrique R, Hoque MO et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8.
15. Konishi N, Nkamura M, Kishi M, Nishimine M, Ishida E, Shimada K. DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn J Cancer Res 2002; 93: 767-73.
16. Kang GH, Le S, Lee HJ, Hwang KS. Abberant CpG island hypermethyaltion of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-40.
17. Hoque MO, Topaloglu O, Berum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005; 23: 6569-75.
18. Nakayama T, Watanabe M, Yamanaka M et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest 2001; 81: 1049-57.
19. Chang YS, Wang L. Correlation between Insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002; 8: 3669-75.
20. Hanafusa T, Yumoto Y. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermehylation in human hepatocellular carcinoma. Cancer Lett 2002; 176: 149-58.
21. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139-55.
22. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the cavelonin-1 gene promoter in prostate cancer. Prostate 2001; 46: 249-56.
23. Khosravi J, Diamandi A, Mistry J, Scorias A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001; 86: 694-9.
24. Tennant MK, Tharasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996; 81: 411-20.
25. Knety H, Madiar Y, Dagan Y, Levi J, Papa MZ, Pariente C. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77: 229-33.
26. Wolk A, Mantzoros CS, Andersson SO et al. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-15.
27. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563-6.
28. Miyata Y, Sakai H, Hayashi T, Kanetake H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003; 54: 125-32.
29. Schildkraut JM, Demark-Wahnefried W, Wenham RM et al. IGF1 (CA) 19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 2005; 14: 403-8.
30. Freidrichsen DM, Hawley S, Shu J et al. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 2005; 65: 44-51.